Vancomycin pharmacokinetics in patients with severe burn injuries

Burns

Volumn 36, Issue 4, 2010, Pages 469-476

  Dolton, Michael ^a   Xu, Hongmei ^a   Cheong, Elaine ^b   Maitz, Peter ^b   Kennedy, Peter ^b   Gottlieb, Thomas ^b   Buono, Evette ^b   McLachlan, Andrew J ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Burn injury; Clearance; MRSA; Pharmacokinetics; Vancomycin

Indexed keywords

VANCOMYCIN;

ARTICLE; BACTERICIDAL ACTIVITY; BURN; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG MONITORING; DRUG RESISTANCE; FEMALE; HOSPITAL PATIENT; HUMAN; INJURY SEVERITY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BURNS; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RETROSPECTIVE STUDIES; VANCOMYCIN; YOUNG ADULT;

EID: 77950521416     PISSN: 03054179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.burns.2009.08.010     Document Type: Article

References (36)

1. Levine D.P. Vancomycin: a history. Clin Infect Dis 42 Suppl. 1 (2006) S5-12
2. Moellering Jr. R.C. Monitoring serum vancomycin levels: climbing the mountain because it is there?. Clin Infect Dis 18 (1994) 544-546
3. Rybak M.J. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 42 Suppl. 1 (2006) S35-S39
4. Saunders N.J. Why monitor peak vancomycin concentrations?. Lancet 344 (1994) 1748-1750
5. Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis 42 (2006) S25
6. Fridkin S.K. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 32 (2001) 108-115
7. Sakoulas G., Moellering Jr. R.C., and Eliopoulos G.M. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis 42 (2006) S40
8. Ansermino M., and Hemsley C. Intensive care management and control of infection. BMJ 329 (2004) 220-223
9. Rice T.L. Simplified dosing and monitoring of vancomycin for the burn care clinician. Burns 18 (1992) 355-361
10. Rybak M.J., Albrecht L.M., Berman J.R., Warbasse L.H., and Svensson C.K. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 34 (1990) 792-795
11. Bonate P.L. Pathophysiology and pharmacokinetics following burn injury. Clin Pharmacokinet 18 (1990) 118-130
12. Boucher B.A., Kuhl D.A., and Hickerson W.L. Pharmacokinetics of systemically administered antibiotics in patients with thermal injury. Clin Infect Dis 14 (1992) 458-463
13. Jaehde U., and Sorgel F. Clinical pharmacokinetics in patients with burns. Clin Pharmacokinet 29 (1995) 15-28
14. Weinbren M.J. Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother 44 (1999) 319
15. Bailie GRA B.H., Fischer J., Solem L.D., and Rotschafer J.C. Increased vancomycin dosage requirements in young burn patients. J Burn Care Rehabil 5 (1984) 376-378
16. Brater D.C., Bawdon R.E., Anderson S.A., Purdue G.F., and Hunt J.L. Vancomycin elimination in patients with burn injury. Clin Pharmacol Ther 39 (1986) 631-634
17. Garrelts J.C., and Peterie J.D. Altered vancomycin dose vs. serum concentration relationship in burn patients. Clin Pharmacol Ther 44 (1988) 9-13
18. Rotschafer J.C., Crossley K., Zaske D.E., Mead K., Sawchuk R.J., and Solem L.D. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 22 (1982) 391-394
19. Rayner C. Vancomycin-digging bigger troughs?. Aust Soc Antimicrob Newslett September (2003) 5-7
20. Saunders N.J. Vancomycin administration and monitoring reappraisal. J Antimicrob Chemother 36 (1995) 279-282
21. Connolly S., Darton A., Brady M., Cambell P., Darke J., Elfleet D., et al. Clinical practice guidelines: burn wound management. NSW Severe Burn Injury Service (2006), NSW Health, Australia
22. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
23. Rossi S. Australian medicines handbook. 7th ed. (2006), Australian Medicines Handbook Pty. Ltd., Adelaide, Australia
24. Loirat P., Rohan J., Baillet A., Beaufils F., David R., and Chapman A. Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin. New Engl J Med 299 (1978) 915-919
25. Nivoche Y., Contrepois A., Cremieux A.C., and Carbon C. Vancomycin in rabbits: pharmacokinetics, extravascular diffusion, renal excretion and interactions with furosemide. J Pharmacol Exp Ther 222 (1982) 237-240
26. Rodvold K.A., Blum R.A., Fischer J.H., Zokufa H.Z., Rotschafer J.C., Crossley K.B., et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 32 (1988) 848-852
27. Cantu T.G., Yamanaka-Yuen N.A., and Lietman P.S. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 18 (1994) 533-543
28. Leader W.G., Chandler M.H., and Castiglia M. Pharmacokinetic optimisation of vancomycin therapy. Clin Pharmacokinet 28 (1995) 327-342
29. Duffull S.B., Chambers S.T., and Begg E.J. How vancomycin is used in australasia-a survey. Aust NZ J Med 23 (1993) 662-666
30. Duffull S.B., Begg E.J., Chambers S.T., and Barclay M.L. Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model. Antimicrob Agents Chemother 38 (1994) 2480-2482
31. Larsson A.J., Walker K.J., Raddatz J.K., and Rotschafer J.C. The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J Antimicrob Chemother 38 (1996) 589-597
32. Poulos V, Fisher M. Vancomycin: serum/plasma. CSLS Handbook of laboratory medicine [online]. Sydney, Australia. www.cs.nsw.gov.au/csls/ Central Sydney Laboratory Service [accessed June 2009].
33. Cruciani M., Gatti G., Lazzarini L., Furlan G., Broccali G., Malena M., and Concia E. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 38 (1996) 865-869
34. Zokufa H.Z., Solem L.D., Rodvold K.A., Crossley K.B., Fischer J.H., and Rotschafer J.C. The influence of serum albumin and alpha 1-acid glycoprotein on vancomycin protein binding in patients with burn injuries. J Burn Care Rehabil 10 (1989) 425-428
35. Albanese J., Leone M., Bruguerolle B., Ayem M.L., Lacarelle B., and Martin C. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother 44 (2000) 1356-1358
36. Rong-hua Y., Xin-zhou R., Rong H., and Tao Z. Pharmacokinetics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn. Burns 35 (2009) 75-79